Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

NCT05752552 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Adult Solid Tumor
Advanced Solid Tumor
Refractory Tumor
Non-small Cell Lung Cancer
Non-small Cell Carcinoma
Lung Cancer
Hereditary Renal Papillary Cancer

Interventions

DRUG: DO-2

Sponsor

DeuterOncology